This session will review the recent literature on radiation for upper and lower GI cancers. Specific cancers that will be addressed are esophageal cancer, gastric cancer, pancreatic cancer, and biliary tract cancer. Trials that utilize radiotherapy will be discussed. The audience will know when the appropriate clinical scenarios that radiation may offer benefit and those scenarios where radiotherapy may not be appropriate.
The treatment paradigms for the management of rectal cancers continues to evolve with more data emerging on short course radiotherapy, total neoadjuvant therapy, and the development of non-operative management algorithms. Given the rapid evolution an understanding of the available data is crucial to the practitioner to provide high quality and cost-effective care to patients. For anal cancers, a malignancy treated definitively with chemoradiation, advances in radiotherapy techniques has reduced significant toxicity in this patient cohort. An in depth understanding of radiotherapy simulation, treatment planning and treatment delivery for anorectal cancers will be provided that can be immediately incorporated into clinical practice.
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this live activity, attendees should be able to do the following:
1. Recognize when the appropriate circumstances are to offer radiotherapy for gastric cancer.
2. Distinguish the role or preoperative chemoradiotherapy for esophageal cancer.
3. Identify the appropriate circumstances to utilize radiotherapy for pancreatic cancer.
4. Discuss the role of radiation for biliary tract cancers in the adjuvant and definitive settings.
1. Distinguish the available literature to guide treatment decision in the management of lower GI malignancies.
2. Develop techniques in simulation, treatment planning and treatment delivery to optimize radiotherapy delivery and minimize associated toxicities.
Daniel Chang, MD, is employed by Stanford University and receives compensation/remuneration/funding from Varian Medical Systems and has stock in ViewRay
Manisha Palta, MD, is employed by Duke Cancer Institute and compensation/remuneration/funding from Merck and Varian.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.